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Background: Transcatheter Aortic Valve Implantation (TAVI) is now considered an indispensable treatment strat-
egy in high operative risk patients with severe, symptomatic aortic stenosis. However, conduction disturbances
and the need for Permanent Pacemaker (PPM) implantation after TAVIwith the CoreValve prosthesis still remain
frequent.
Methods and results:We aimed to evaluate the implantation depth, the incidence and predictors of new conduc-
tion disturbances, and the need for PPM implantation within the ﬁrst month after TAVI, using the new Accutrak
CoreValve delivery system (ACV), compared to the previous generation CoreValve (non-ACV). In 5 experienced
TAVI-centers, a total of 120 consecutive non-ACV and 112 consecutive ACV patients were included (n = 232).
The mean depth of valve implantation (DVI) was 8.4 ± 4.0 mm in the non-ACV group and 7.1 ± 4.0 mm in
the ACV group (p = 0.034). The combined incidence of new PPM implantation and new LBBB was 71.2% in
the non-ACV group compared to 50.5% in the ACV group (p = 0.014). DVI (p = 0.002), ﬁrst degree AV block
(p = 0.018) and RBBB (p b 0.001) were independent predictors of PPM implantation. DVI (p b 0.001) and
pre-existing ﬁrst degree AV-block (p = 0.021) were identiﬁed as signiﬁcant predictors of new LBBB.
Conclusion:DVI is an independent predictor of TAVI-related conduction disturbances and can be reduced by using
the newer CoreValve Accutrak delivery system, resulting in a signiﬁcantly lower incidence of new LBBB and new
PPM implantation.© 2014 Published by Elsevier Ireland Ltd.1. Introduction
Transcatheter Aortic Valve Implantation (TAVI) has become the
treatment of choice for inoperable patients with severe, symptomatic
aortic stenosis and a valuable alternative for those with high operative
risk [1–3]. However, TAVI performed with the self-expanding
Medtronic CoreValve ® device (CV) is frequently complicated by
new conduction disturbances and subsequent need for Permanent
Pacemaker (PPM) implantation. Due to intrinsic properties of the de-
livery catheter, the use of the ﬁrst generation 18Fr CV often resultednberg, Victor Legrand, Peter den
for Medtronic CoreValve.
erp, Wilrijkstraat 10, B-2650
49 09.
).
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Cardiol (2014), http://dx.doi.oin anatomically deep valve implantation. It has been hypothesized
that trauma to the interventricular septum by deep insertion of the
nitinol frame could impede the conduction tissue which it embeds,
resulting in a high incidence of new Left Bundle Branch Block (LBBB)
or complete AV-block after valve implantation [4,5]. This might explain
the relatively high rate of new pacemaker implantation, as consistently
reported by several TAVI registries [6,7].
The Accutrak delivery catheter for the CV has an additional stability
layer by which friction forces are reduced, resulting in a more con-
trolled and accurate positioning of the CV. Therefore it was hypothe-
sized that using the Accutrak delivery catheter could result in a
higher valve implantation, inﬂicting a milder trauma to surrounding
structures and conduction tissue resulting in a decreased need of
new pacemaker implantation. However, only few comparative data
are available at present [8].
The pre-speciﬁed primary aim of this multi-center Accutrak conduc-
tion studywas to evaluate the implantation depth, the incidence of newonduction disturbances and pacemaker implantation with CoreValve
rg/10.1016/j.ijcard.2014.07.092
2 G.D. Lenders et al. / International Journal of Cardiology xxx (2014) xxx–xxxconduction disturbances, and the need for and indications of PPM im-
plantation within the ﬁrst month after TAVI, using the new Accutrak
CV delivery system (ACV), compared to the previous generation CV
(non-ACV) in a consecutive “real world” patient population. In addition,




A total of 232 patients were included in 5 high-volume centers experienced in
performing TAVI with the CV prosthesis between January 2008 andMay 2011. All centers
were asked to include the ﬁrst 20 to 25 consecutive patients before and after implementa-
tion of the Accutrak delivery system after excluding 5 “learning curve” patients. Finally,
each center included 17 to 25 consecutive non-Accutrak patients (non-ACV group) and af-
terwards 21 to 25 consecutive Accutrak patients (ACV group). All patients had severe
symptomatic aortic valve stenosis, with (very) high operative risk. TAVI implantation
was considered feasible by the local heart team, consisting of cardiologists, interventional
cardiologists, cardiac surgeons and anaesthesiologists. All patients underwent TAVI with
the CV prosthesis.
2.2. Data collection and processing
Age, gender, logistic EuroSCORE, themean gradient of the aortic stenosis, Aortic Valve
Area (AVA), presence of atrial ﬁbrillation (AF), pre-existing LBBB and RBBB, pre-existing
1st degree AV-block and previous PM implantation were assessed in all patients. ECG
was performed before, after, at hospital discharge and at 1 month follow-up after TAVI.
Vascular access site and size of the prosthesis were assessed for all procedures. Depth of
valve implantation (DVI) was assessed in a central core lab (Antwerp University Hospital)
based on procedural ﬁnal angiography performed immediately after TAVI. Blinded mea-
surements were made by one operator (VC), to ensure consistency of the results, using
IMPAX Cardiovascular Information System (Agfa Healthcare, Mortsel, Belgium) and
CAAS system (PieMedical Imaging,Maastricht, The Netherlands) software. First, an angio-
graphic projection in which the three sinuses of the aortic valve were seen in the same
plane (annular perpendicular view) was chosen as a reference. Secondly, the lower
edges of the three cusps of the aortic valve were connected to form a reference line. Per-
pendicular to this line, the implantation depth of the CoreValve prosthesis was measured
medial (interventricular septum) and lateral. The mean of these two measurements was
considered the correct DVI in the left ventricular outﬂow tract. DVI was quantitatively
measured in mm beneath the aortic annulus and a mean depth of 4–6 mm beneath the
aortic annulus was considered “normal”. Fig. 1 shows a high (A) and low (B) TAVI implan-
tation. Calibration was done using the 5 French pigtail-catheter as a reference. Intraclass
correlation was used to test for reproducibility. A total of 15 random measurements
were repeated with an intraclass correlation coefﬁcient of 0.96. One center (Malaga) per-
formed, in a similar way, their own measurements of DVI both in ACV patients and non-
ACV patients, excluding possible bias.
New PPM-implantation was assessed until 30 days after the procedure and indica-
tions were classiﬁed according to the ESC-guidelines for PPM implantation [9].Fig. 1. Angiography in LAO of a fully deployed CoreValve after a high (A) and a low (B) implan
depicted.
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The combined primary endpoint for the need for new PPM implantation and the oc-
currence of new LBBB (not requiring new PPM implantation), in the ﬁrst month after
TAVI, was compared between the ACV group and the non-ACV group. Secondly, DVI was
compared between both groups and the relationship with signiﬁcant conduction distur-
bances was assessed. Finally, possible predictors for the need of new PPM implantation
and the occurrence of LBBB were analyzed.2.4. Statistical analysis
Statistical analysis for the studywas performedusing SPSS software version 20.0 (IBM
Corporation, New York). Categorical variables were expressed as percentages and were
compared using Chi Square tests. Fisher's exact test was performedwhen applicable. Con-
tinuous variables were expressed as mean ± SD and were compared using unpaired
Student t-tests when normal distribution occurred. Mann–Whitney U-tests were used in
case of abnormal distribution. Correlation between baseline characteristics and the
CoreValve type were determined by binary logistic regression. All p-values were 2-sided
and differences were considered statistically signiﬁcant when p b 0.05.3. Results
3.1. Baseline patient and procedural characteristics
A total of 232 consecutive patients – 120 non-ACV and 112 ACV
patients – were included between May 2007 and December 2011.
Baseline patient and procedural characteristics are presented in
Table 1. No signiﬁcant differences in baseline characteristics between
the two patient groups could be detected. The mean age was 81.7 ±
6.0 years, mean logistic EuroSCORE was 22.2 ± 14.3% and mean AVA
was 0.62± 0.16 cm [2], reﬂecting a typical TAVI populationwith severe
aortic valve stenosis, old age and high risk for surgical valve replace-
ment. Pre-procedural ECG-analysis demonstrated atrial ﬁbrillation
(AF) in 37 patients (15.9%). Eighteen patients had already a PPM
(7.8%) and were excluded from analysis. RBBB was present in 26 pa-
tients (12.10%), LBBB in another 26 patients (12.1%) while 1st degree
AV block was present in 33 patients (15.4%).
In the majority of patients TAVI was performed by femoral access
(N90%). Subclavian access was used in only 12 patients (10%) in the
non-ACV group and 8 patients (7%) in the ACV group. Three patients
in the ACV group were treated by direct aortic access. Both 26 mm
valve size and 29 mm valve size were used almost equally in both the
non-ACV and ACV groups. The 23 mm and 31 mm CV devices were
not yet widely available at the time of this study. Post dilatation wastation beneath the aortic annulus. Medial and lateral DVI (depth of valve implantation) is
onduction disturbances and pacemaker implantation with CoreValve
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Table 1
Baseline and procedural characteristics. Categorical and continuous variables.
Non-AMCV (n = 120) AMCV (n = 112) Total (n = 232) p-Value
Age (years) —mean ± SD 82.0 ± 5.2 81.4 ± 6.8 81.7 ± 6.0 0.412
Male — n (%) 56 (46.7) 45 (40.2) 101 (43.5) 0.319
Logistic EuroSCORE (%) —mean ± SD 21.1 ± 12.6 23.5 ± 15.9 22.2 ± 14.3 0.466
AVA (cm2) —mean ± SD 0.64 ± 0.14 0.61 ± 0.18 0.62 ± 0.16 0.157
Mean gradient AV (mm Hg) —mean ± SD 47.7 ± 14.3 47.7 ± 13.1 47.7 ± 13.7 0.968
Previous AF — n (%) 16 (13.3) 21 (18.8) 37 (15.9) 0.245
Previous pacemaker — n (%) 10 (8.3) 8 (7.14) 18 (7.8) 0.735
RBBB — n (%) 14 (11.7) 12 (10.7) 26 (11.2) 0.832
LBBB — n (%) 15 (12.5) 11 (9.8) 26 (11.2) 0.528
1st degree AV block — n (%) 18 (15) 15 (13.4) 33 (14.2) 0.781
Transfemoral — n (%) 108 (90.0) 101 (90.2) 209 (90.1) 0.964
Transsubclavian — n (%) 12 (10.0) 8 (7.1) 20 (8.6) 0.438
Direct aortic — n (%) 0 (0) 3 (2.7) 3 (1.3) 0.111
26 mm CoreValve — n (%) 49 (40.8) 54 (48.2) 103 (44.4) 0.258
29 mm CoreValve — n (%) 71 (59.2) 58 (51.8) 129 (55.6) 0.205
Post dilatation — n (%) 20 (16.7) 24 (21.4) 44 (18.9) 0.324
AMCV: Accutrack Medtronic CoreValve; AVA: Aortic valve area; AF: Atrial ﬁbrillation; RBBB: Right Bundle Branch Block; LBBB: Left Bundle Branch Block.
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21.4% in the ACV group).3.2. Depth of valve implantation, conduction disturbances and pacemaker
implantation
Table 2 summarizes the mean DVI and the incidence of new PPM
implantations, new conduction disturbances and mortality at
30 days. The mean DVI was 8.4 ± 4.0 mm in the non-ACV group
and 7.1 ± 4.0 mm in the ACV group (p = 0.034). In patients without
PPM or LBBB before valve implantation, the combined incidence of
new PPM implantation and new LBBB (primary endpoint) was
71.2% in the non-ACV group compared to 50.5% in the ACV group
(p = 0.014). In the non-ACV group, 33 (32.3%) “pacemaker naïve”
patients received PPM after valve implantation compared to 21
(21.4%) “pacemaker naïve” patients in the ACV group (p = 0.094).
In the non-ACV group, 29 (33.3%) “LBBB-naïve patients” developed
new LBBB without a need for new PPM at discharge, compared to
23 (26.4%) “LBBB-naïve patients” in the ACV group (p = 0.320).
The occurrence of a new RBBB in “RBBB-naïve patients” was rare and
did not differ between both groups (p= 1.000) nor did the occurrence
of new 1st degree AV-block after valve implantation (p = 0.909). The
30 day all-cause mortality was low and not signiﬁcantly different be-
tween the non-ACV group (6.7%) and the ACV group (5.4%).
Most pacemakers were implanted because of 3rd degree AV-block
(67% in the non-ACV group and 76% in the ACV group) without any sta-
tistical difference in all classes of indications for pacemaker implanta-
tion (Table 3). Most PPMs were implanted in the ﬁrst week after TAVI,
both in the ACV and non-ACV groups.Table 2
DVI, new Permanent Pacemaker (PPM) implantations, conduction disturbances and all-
cause mortality, 30 days after TAVI.
Non-AMCV AMCV Total p-Value
DVI (mm) —mean ± SD 8.4 ± 4.0 7.1 ± 4.0 7.7 ± 4.1 0.034
New PPM + new LBBB — n (%) a 73 (76.8) 53 (56.9) 126 (67.0) 0.014
New PPM — n (%) b 32 (29.1) 21 (20.2) 53 (24.8) 0.082
New LBBB — n (%) a 41 (43.2) 32 (34.4) 73 (38.8) 0.053
New RBBB — n (%) c 1 (1.0) 4 (4.3) 5 (2.7) 0.368
New 1st degree AV block — n (%) d 13 (17.1) 15 (22.1) 28 (19.4) 0.742
All-cause 30 day mortality — n (%) 8 (6.7) 6 (5.4) 14 (6.0) 0.676
AMCV: Accutrack Medtronic CoreValve; PPM: Permanent Pacemaker; LBBB: Left Bundle
Branch Block; RBBB: Right Bundle Branch Block; AV: Atrio Ventricular.
Bold values indicate signiﬁcance at p b 0.05.
a Patients with previous PPM or previous LBBB excluded (n = 188).
b Patients with previous PPM excluded (n = 214).
c Patients with previous PPM or previous RBBB excluded (n = 188).
d Patients with previous PPM. 1st degree AV-block and AF excluded (n = 144).
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tation, for both the non-ACV and ACV groups, is presented in Table 4
and Fig. 2. The mean DVI in all patients (combined ACV and non-
ACV) that required new PPM implantation (n = 54) was 8.9 ±
4.2 mm, which is signiﬁcantly lower compared to those who did
not need new PPM implantation with a mean DVI of 6.9 ± 3.8 mm
(p = 0.002). In the non-ACV group this difference remains signiﬁ-
cant with a mean DVI of 9.4 ± 4.2 mm in patients receiving PPM im-
plantation compared to 7.3 mm ± 3.7 in those who did not (p =
0.022). A trend remained also in the ACV group, with the mean DVI
of 8.2 ± 4.2 mm in patients receiving pacemaker implantation com-
pared to 6.6 mm ± 4.1 in those who did not (p = 0.115).
The relationship between DVI and new LBBB is also statistically
signiﬁcant with a lower implantation in the patients with a new
LBBB (8.8 ± 3.5 mm) compared with those without a new LBBB
(5.4 ± 3.5 mm). This difference remains statistically signiﬁcant in
both the non-ACV group and the ACV group (Table 5).
3.3. Predictors
In a univariate analysis of the total population of both ACV and non-
ACV patients, pre-existing 1st degree AV block (p = 0.018), pre-
existing RBBB (p b 0.001) and DVI (p = 0.002) were predictors of
new PPM implantation at 30 days after TAVI (Table 6). In Table 7, a
similar univariate analysis of the total study population is depicted
for the occurrence of a new LBBB (only signiﬁcant predictors and
the use of the Accutrak catheter are shown). DVI and pre-existing
1st degree AV-block were identiﬁed as signiﬁcant predictors.
4. Discussion
The pre-speciﬁed primary aim of this multi-center conduction study
was to evaluate the implantation depth, the incidence of new conduc-
tion disturbances, and the need for and indications of PPM implantationTable 3








3rd degree AV block — n (%) 21 (65.6) 16 (76.2) 37 (69.8) 0.412
New LBBB — n (%) 3 (9.4) 3 (14.3) 6 (11.3) 1.000
New 1st degree AV block — n (%) 1 (3.1) 0 (0) 1 (1.9) 0.625
1st degree AV block + LBBB — n (%) 4 (12.5) 0 (0) 4 (7.5) 0.143
Signiﬁcant bradycardia — n (%) 3 (9.4) 2 (9.5) 5 (9.4) 0.755
PPM: Permanent Pacemaker; ACV: Accutrack CoreValve; AV: Atrio Ventricular; LBBB: Left
Bundle Branch Block.
onduction disturbances and pacemaker implantation with CoreValve
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Table 4
Depth of valve implantation (DVI) versus PPM.
DVI — no PPM
Mean ± SD (mm)
DVI — PPM
Mean ± SD (mm)
p-Value
Non-ACV 7.3 ± 3.7 9.4 ± 4.2 0.022
ACV 6.6 ± 4.1 8.2 ± 4.2 0.115
Total 6.9 ± 3.8 8.9 ± 4.2 0.002
PPM: Permanent Pacemaker; ACV: Accutrack CoreValve.
Bold values indicate signiﬁcance at p b 0.05.
Table 5
Depth of valve implantation (DVI) versus new LBBB.
DVI — no LBBB
mean ± SD (mm)
DVI — LBBB
mean ± SD (mm)
p-Value
Non-ACV 6.15 ± 2.97 8.79 ± 4.09 0.022
ACV 4.97 ± 3.78 8.82 ± 2.92 b0.001
Total 5.40 ± 3.52 8.81 ± 3.51 b0.001
LBBB: Left Bundle Branch Block; ACV: Accutrack CoreValve.
Bold values indicate signiﬁcance at p b 0.05.
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system, compared to the previous generation CV in a consecutive “real
world” patient population. In addition, we aimed to identify predictors
of the occurrence of new PPM implantation and new LBBB. The main
ﬁndings of this study can be summarized as follows:
(1) The incidences of new PPM implantation and new LBBB are con-
ﬁrmed to be high after TAVI, especially when using the “old gen-
eration” non-Accutrak 18Fr CV prosthesis.
(2) Themean depth of valve implantation is conﬁrmed to be a strong
predictor, for both new PPM implantation and new LBBB after
TAVI.
(3) The mean depth of valve implantation is signiﬁcantly reduced
using the “new generation” Accutrak 18Fr CV prosthesis.
(4) The implementation of the “new generation” Accutrak 18Fr CV
prosthesis signiﬁcantly reduced the incidence of the combined
endpoint of new PPM implantation and new LBBB after TAVI.
New conduction disturbances after TAVI remain a major limitation,
especially with the self-expanding CV, with a reported incidence of
PPM implantation varying between 16 and 40% [10–13]. PPM implanta-
tion holds certain procedural risks, especially in an old and frail popula-
tion such as the one that undergoes TAVI (in casu pneumothorax,
bleeding, infection, etc.). Moreover, longstanding RV-pacing on itself
can induce heart failure [14], or prevent left ventricular recovery. Fur-
thermore, the occurrence of conduction disturbances not requiring
PPM implantation after TAVI is high as well. In particular, LBBB has re-
cently been reported to be associated with worse clinical outcome
[15]. Trauma to the IV-septum and subsequently to the conduction tis-
sue it embeds, induced by the relatively deep implanted valve frame,
is considered to be a major determinant for the new conduction distur-
bances occurring after TAVI [16]. Awareness of this post proceduralFig. 2. Depth of valve implantation in patients with and without the need for new Pace-
maker implantation. Clustered error bars of Accutrack patients, non-Accutrack patients
and the combination of both Accutrack and non-Accutrack patients are shown.
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tion and attempts by operators to perform a safer and thus higher
valve implantation. However proper valve positioning has been
shown to be relatively challenging using the “old generation”
CoreValve.
Several predictors for PPM implantation after TAVI have been
identiﬁed, mostly in studies restricted by a relatively small sample
size. Pre-existing RBBB, depth of valve implantation, hypertrophy
of the interventricular septum and pre-existing 1st degree AV-
block have previously been identiﬁed as predictors for the need for
new PPM implantation after TAVI [5,17,18]. In this relatively large,
multi-center study, not only depth of valve implantation, but also
pre-existing RBBB and pre-existing 1st degree AV-block conﬁrmed
to be strong predictors of the need for new PPM implantation. Better
control of depth of valve implantation, especially for the CV, is there-
fore of great clinical relevance in the prevention of conduction dis-
turbances after TAVI.
There is no clearmethodological consensus on how tomeasuremost
accurately DVI below the annulus. In the single center study byMuñoz-
García et al. [19], the distance from the non-coronary cusp to the distal
extreme of the prosthesis, based on angiography after TAVI, was consid-
ered to be the implantation depth. Using this methodology, the
Accutrak delivery system was associated with less deep prosthesis im-
plantation in the left ventricular outﬂow tract, which could be related
to the lower rate of PPM requirement. Also Piazza et al. [20] demonstrat-
ed that themean distance between the proximal end of the CV prosthe-
sis and the lower edge of the non-coronary sinus was signiﬁcantly
shorter in patients who did not need PPM implantation. On the other
hand, Tchetche et al. [8] deﬁned DVI as the maximal distance between
the intraventricular end of the prosthesis and the aortic annulus at the
level of the non-coronary cusp and the left anterior coronary cusp. In
this study, evaluating exclusively the Accutrak system, the mean DVI
was 4.9 ± 2 mm. In our actual study, we deﬁned DVI as the mean of
the distance from the nadir of the non-coronary and left coronary
sinus to the ventricular edge of the frame, demonstrating that DVI is
an independent predictor of TAVI-related conduction disturbances and
can be reduced by using the newer CoreValve Accutrak delivery system.
However, although different methodologies are reported for quantify-
ing depth of valve implantation, complicating interpretation of absolute
implantation depths, a consistent relation between DVI and occurrence
of new conduction disturbances is conﬁrmed by most authors.Table 6
Predictors of new PPM implantation — univariate analysis.
Bold values indicate signiﬁcance at p b 0.05.
No new PPM New PPM p-Value
AVA (cm2) —mean ± SD 0.61 ± 0.16 0.65 ± 0.17 0.122
Male — n (%) 54 (37) 27 (50) 0.096
Pre-existing AVB I — n (%) 17 (14.4) 13 (31) 0.018
Pre-existing LBBB — n (%) 21 (14.5) 4 (7.4) 0.181
Pre-existing RBBB — n (%) 5 (3.4) 19 (35.2) b0.001
DVI (mm beneath annulus) — n (%) 6.87 ± 3.92 8.94 ± 4.19 0.002
Accutrack — n (%) 77 (52.7) 21 (38.9) 0.082
PPM: Permanent Pacemaker; AVA: Aortic Valve Area; AVB: Atrio Ventricular Block; LBBB:
Left Bundle Branch Block; RBBB: Right Bundle Branch Block; DVI: depth of valve
implantation.
Bold values indicate signiﬁcance at p b 0.05.
onduction disturbances and pacemaker implantation with CoreValve
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Table 7
Predictors of new LBBB— univariate analysis.
No new LBBB New LBBB p-Value
DVI (mm beneath annulus) — n (%) 5.4 ± 3.52 8.81 ± 3.51 b0.001
Pre-existing AVB I — n (%) 3 (5.4) 9 (20.5) 0.021
Accutrack — n (%) 42 (60) 23 (44.2) 0.084
LBBB: Left Bundle Branch Block; DVI: depth of valve implantation; AVB: Atrio Ventricular
Block.
Bold values indicate signiﬁcance at p b 0.05.
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multicenter comparative study, performed in 5 high-volume TAVI cen-
ters, in which depth of valve implantation, both of the “old” and “new
generation” 18Fr CV, is measured by a blinded core lab and related to
the occurrence of new conduction abnormalities and new PPM
implantation.
4.1. Study limitations
The present study is of observational nature with the inherent limi-
tations of such a design. However, all patients in all centers have been
included consecutively, without exclusion, representing a “real world”
situation. In addition, the fact that all patients in the Accutrak group
were treated later in time, compared to those treatedwith the older sys-
tem, could have created a bias because the concept of DVI, being poten-
tially responsible for conduction disturbances, may have resulted in
attempts of operators to implant higher and thus safer in later proce-
dures, independent of the new delivery device. We tried to minimize
this potential bias by including the last patients treated with the previ-
ous delivery system and the ﬁrst patients treated with the Accutrak
delivery system in every center, reducing the difference in time to a
minimum.
We also did not implement data about the valve/annulus ratio, an
additional potential risk factor for post procedural conduction distur-
bances because in different centers, different imaging techniques were
used for valve sizing.
A higher valve implantation could hypothetically result in more se-
vere aortic regurgitation although we found no signiﬁcant difference
in our study. But since assessment of aortic regurgitation, in our study,
was done with visual assessment at ﬁnal angiography only, we did not
implement these data in our study.
Also the use of a combined endpoint of new PPM implantation and
new LBBB (without PPM implantation) can appear heterogeneous but
both reﬂect very similar CV related conduction abnormalities and are
important predictors of morbidity and even mortality, so can be taken
in account together.
5. Conclusion
The incidences of TAVI-related new LBBB and new PPM implanta-
tion remain high with the Medtronic CoreValve system. DVI is a sig-
niﬁcant predictor for PPM implantation and new LBBB. The newer
Accutrak delivery catheter can signiﬁcantly reduce DVI, resulting inPlease cite this article as: Lenders GD, et al, Depth of valve implantation, c
and CoreValve Accutrak system for T..., Int J Cardiol (2014), http://dx.doi.oa signiﬁcantly lower incidence of new LBBB and new PPM implantation.
Further equivocal improvements in the conceptual design are needed to
reduce complications if further indications for TAVI are to be extended.
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